Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
Viking Therapeutics initiated the SUNRISE Phase 3 program for oral VK2735, a once-daily dual GLP-1/GIP agonist, with two 68-week trials (SUNRISE-1 and SUNRISE-2) each enrolling 560 adults with obesity, with and without type 2 diabetes. The move follows positive Phase 2 VENTURE-Oral results showing up to 12.2% mean body-weight reduction at 13 weeks, with up to 97% of patients achieving at least 5% weight loss.
Key figures
- Drug Name
- VK2735 (oral)
- Phase Of Trial
- Phase 3
- Doses mg
- [27.5,35,55]
- Trial names
- ["SUNRISE-1","SUNRISE-2"]
- Enrollment per trial
- 560
- Vanquish 1 enrollment
- 4500
- Vanquish 2 enrollment
- 1000
- Phase2 weight loss up to
- 12.2%
- Treatment duration weeks
- 68
- Patients achieving 5pct weight loss
- 97%
- Patients achieving 10pct weight loss
- 80%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.